<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759861</url>
  </required_header>
  <id_info>
    <org_study_id>121-16</org_study_id>
    <nct_id>NCT02759861</nct_id>
  </id_info>
  <brief_title>Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics</brief_title>
  <official_title>A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of Harvoni in treatment-naïve alcoholic subjects with&#xD;
      Genotype 1 HCV infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      determine the cure rate of Harvoni in treatment naïve alcoholic subjects with Genotype 1 HCV&#xD;
      infection&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects who achieve negative RNA in alcoholics</measure>
    <time_frame>12 weeks after the end of Harvoni therapy</time_frame>
    <description>determined by blood draw</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Genotype 1 Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Harvoni x 8 or 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive 8 or 12 weeks depending on clinical data</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>harvoni</intervention_name>
    <description>8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy</description>
    <arm_group_label>Harvoni x 8 or 12 weeks</arm_group_label>
    <other_name>Ledipasvir/Sofosbuvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject must be willingly and able to provide written informed consent&#xD;
&#xD;
          2. Age 19 years of age or older (The age of consent in Nebraska)&#xD;
&#xD;
          3. HCV treatment-naïve, as defined as no prior exposure to any Interferon (IFN), RBV, or&#xD;
             other FDA approved or experimental HCV-specific direct-acting antiviral agent&#xD;
&#xD;
          4. HCV RNA level at most 6 months prior to the Baseline/Day 1 visit.&#xD;
&#xD;
          5. HCV genotyping 1a, 1b, or mixed 1a/ab. Any non-definitive results will exclude the&#xD;
             subject from study participation.&#xD;
&#xD;
          6. Alcohol misuse as defined by the Alcohol Use Disorders Identification Test (AUDIT)&#xD;
             score subjects must score &gt; 8 (associated with harmful or hazardous drinking)&#xD;
&#xD;
          7. Cirrhosis determination [up to 20% of study subjects may have cirrhosis]:&#xD;
&#xD;
               1. Cirrhosis is defined as any one of the following:&#xD;
&#xD;
                    -  History of a liver biopsy showing cirrhosis (e.g. Metavir score = 4 or Ishak&#xD;
                       score &gt; 5)&#xD;
&#xD;
                    -  Fibroscan showing cirrhosis or results &gt; 12.5 kPa&#xD;
&#xD;
                    -  FIBRO Spect II index consistent with F3 or F4 AND an AST : platelet ration&#xD;
                       index (APRI) of &gt; 2 during Screening&#xD;
&#xD;
               2. Absence of cirrhosis is defined as any one of the following:&#xD;
&#xD;
                    -  Liver biopsy within 2 years of Screening showing absence of cirrhosis&#xD;
&#xD;
                    -  Fibroscan within 6 months of Baseline/Day1 with a result of ≤ 12.5 kPa&#xD;
&#xD;
                    -  FIBRO Spect II Index consistent with F0- F2 AND APRI of ≤ 1 during Screening&#xD;
&#xD;
          8. Liver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma&#xD;
             HCC) is required&#xD;
&#xD;
          9. Subjects must have the following laboratory parameters at screening:&#xD;
&#xD;
               1. ALT &lt; 10 x the upper limit of normal (ULN)&#xD;
&#xD;
               2. AST &lt; 10 x ULN&#xD;
&#xD;
               3. Direct bilirubin &lt; 2.0 x ULN&#xD;
&#xD;
               4. Platelets &gt; 50,000&#xD;
&#xD;
               5. HbA1c &lt; 8.5%&#xD;
&#xD;
               6. Creatinine clearance (CLcr) ≥ 60 mL /min, as calculated by the Cockcroft-Gault&#xD;
                  equation&#xD;
&#xD;
               7. Hemoglobin ≥ 11 g/dL for female subjects; ≥ 12 g/dL for male subjects.&#xD;
&#xD;
               8. Albumin ≥ 2.5 g/dL&#xD;
&#xD;
               9. INR ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an&#xD;
                  anticoagulant regimen affecting INR.&#xD;
&#xD;
         10. Subject has not been treated with any investigational drug or device within 30 days of&#xD;
             the screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women and nursing mothers are ineligible due to the possible risk of adverse&#xD;
             effects in the newborn. Eligible patients of reproductive potential should use&#xD;
             adequate contraception if sexually active.&#xD;
&#xD;
          2. Serious concurrent medical illness which would jeopardize the ability of the subject&#xD;
             to receive the therapy as outlined in this protocol with reasonable safety.&#xD;
&#xD;
          3. Malignancy diagnosed or treated within 5 years (recent localized treatment of squamous&#xD;
             or non-invasive basal cell skin cancers is permitted; cervical carcinoma in situ is&#xD;
             allowed if appropriately treated prior to screening); subjects under evaluation for a&#xD;
             malignancy are not eligible.&#xD;
&#xD;
          4. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)&#xD;
&#xD;
          5. Use of any prohibited concomitant medications within 30 days of the Baseline/Day 1&#xD;
             visit.&#xD;
&#xD;
          6. Known hypersensitivity to LDV/SOF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Mailliard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>680017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>with Gilead Inc.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

